[go: up one dir, main page]

UY23697A1 - Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo - Google Patents

Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo

Info

Publication number
UY23697A1
UY23697A1 UY23697A UY23697A UY23697A1 UY 23697 A1 UY23697 A1 UY 23697A1 UY 23697 A UY23697 A UY 23697A UY 23697 A UY23697 A UY 23697A UY 23697 A1 UY23697 A1 UY 23697A1
Authority
UY
Uruguay
Prior art keywords
radical
formula
deoxy
integer
protecting groups
Prior art date
Application number
UY23697A
Other languages
English (en)
Inventor
Motohiro Arasaki
Hideo Ishitsuka
Isami Kuruma
Masanori Miwa
Chikako Murasaki
Nobuo Shimma
Isao Umeda
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY23697(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY23697A1 publication Critical patent/UY23697A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al procedimiento para preparar un compuesto de fórmula general (I) (ver figura 1) derivados de N4-(oxicarbonil sustituidos)-5'-desoxi-5-fuorocitidina, así como también hidratos o solvatos de dichos compuestos, donde: R1 es un radical hidrocarburo saturado o insaturado; R2 es un átomo de hidrógeno o un radical fácilmente hidrolizable en condiciones fisiológicas. El procedimiento comprende la reacción de un compuesto de fórmula general (II) (figura 2), donde R4 es un radical de protección de los hidroxilos con un compuesto: R1OCOC1, y si es necesario se eliminan los radicales de protección. Ejemplo no limitante: 5'-desoxi-5-fluoro-N4-[(1,1,2-trimetilpropoxi)carbonil]citidina. Los productos según la invención son de utilidad para el tratamiento de tumores.
UY23697A 1992-12-18 1993-12-17 Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo UY23697A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92121538 1992-12-18

Publications (1)

Publication Number Publication Date
UY23697A1 true UY23697A1 (es) 1994-06-08

Family

ID=8210304

Family Applications (1)

Application Number Title Priority Date Filing Date
UY23697A UY23697A1 (es) 1992-12-18 1993-12-17 Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo

Country Status (41)

Country Link
US (1) US5472949A (es)
EP (1) EP0602454B1 (es)
JP (1) JP2501297B2 (es)
KR (1) KR100347218B1 (es)
CN (1) CN1035617C (es)
AT (1) ATE137244T1 (es)
AU (1) AU671491B2 (es)
BG (1) BG61485B1 (es)
BR (1) BR9305089A (es)
CA (1) CA2103324C (es)
CZ (1) CZ284788B6 (es)
DE (1) DE69302360T2 (es)
DK (1) DK0602454T3 (es)
EE (1) EE03086B1 (es)
ES (1) ES2086856T3 (es)
FI (1) FI112365B (es)
GE (1) GEP20074251B (es)
GR (1) GR3020286T3 (es)
HK (1) HK1005875A1 (es)
HR (1) HRP931430B1 (es)
HU (2) HU218291B (es)
IL (1) IL108000A0 (es)
IS (1) IS4108A (es)
LT (1) LT3115B (es)
LV (1) LV10625B (es)
MY (1) MY109282A (es)
NO (1) NO300066B1 (es)
NZ (1) NZ250414A (es)
PH (1) PH30168A (es)
PL (1) PL174100B1 (es)
RO (1) RO112619B1 (es)
RU (2) RU2458932C2 (es)
SA (1) SA93140409B1 (es)
SI (1) SI9300648B (es)
SK (1) SK281403B6 (es)
SV (1) SV1993000080A (es)
TW (1) TW372239B (es)
UA (1) UA39158C2 (es)
UY (1) UY23697A1 (es)
YU (1) YU49411B (es)
ZA (1) ZA939293B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
IL141951A0 (en) * 1998-09-25 2002-03-10 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
CA2401191C (en) 2000-02-28 2006-05-02 Aventis Pharma S.A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AU2001246863A1 (en) * 2000-04-11 2001-10-23 Sayuri Yamada Curcumin compositions
KR100730768B1 (ko) * 2000-08-09 2007-06-21 코오롱생명과학 주식회사 5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
GB0113374D0 (en) * 2001-06-04 2001-07-25 Jerram Clare Washing line umbrella
WO2003057217A1 (en) * 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
MXPA05003431A (es) * 2002-11-15 2005-07-05 Warner Lambert Co Quimioterapia de combinacion.
AU2003233586A1 (en) * 2003-05-20 2005-01-21 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
KR20080046752A (ko) * 2003-12-22 2008-05-27 에프. 호프만-라 로슈 아게 플루오로시티딘 유도체에 대한 방법
DK1848414T3 (da) 2005-02-03 2011-07-25 Gen Hospital Corp Fremgangsmåde til behandling af gefitinib-resistent cancer
AU2006228581A1 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
CN101242822B (zh) 2005-07-18 2011-08-24 彼帕科学公司 治疗卵巢癌的药物
JP2009501734A (ja) 2005-07-21 2009-01-22 ヌボ・リサーチ・インコーポレイテッド 癌の治療方法
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
LT2426129T (lt) 2005-12-13 2017-02-10 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
KR20100015568A (ko) * 2007-04-20 2010-02-12 닥터 레디스 레보러터리즈 리미티드 카페시타빈의 제조 방법
WO2008145403A1 (en) * 2007-06-01 2008-12-04 Synthon B.V. Processes related to making capecitabine
RS54878B1 (sr) 2007-06-13 2016-10-31 Incyte Holdings Corp Kristalne soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropionitril
US7842675B2 (en) * 2007-09-15 2010-11-30 Protia, Llc Deuterium-enriched capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
EP2225566A1 (en) * 2008-01-03 2010-09-08 Plus Chemicals S.A. Process for the preparation of capecitabine
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
KR101922096B1 (ko) 2008-06-17 2018-11-27 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
DK2326329T3 (en) 2008-08-04 2017-02-20 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
HRP20230315T1 (hr) 2009-04-06 2023-05-12 Wyeth Llc Režim liječenja raka dojke korištenjem neratiniba
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
UA106078C2 (uk) 2009-05-22 2014-07-25 Інсайт Корпорейшн 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ
JP2012533618A (ja) * 2009-07-23 2012-12-27 サイノファーム タイワン リミテッド フルオロシチジン誘導体の製造プロセス
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) * 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine
MX364636B (es) 2010-03-10 2019-05-03 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
HUE040107T2 (hu) 2010-03-12 2019-02-28 Genzyme Corp Kombinációs terápia mellrák kezelésére
SI2574168T1 (sl) 2010-05-21 2016-07-29 Incyte Holdings Corporation Topična formulacija zaviralca jak
CN102260309B (zh) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 一种高纯度卡培他滨的制备方法
SG190839A1 (en) 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN102558262A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种高纯度卡培他滨的制备方法
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
JP2015537030A (ja) 2012-11-15 2015-12-24 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ルキソリチニブの徐放性投薬形態
KR102366356B1 (ko) 2013-03-06 2022-02-23 인사이트 홀딩스 코포레이션 Jak 저해제를 제조하기 위한 방법 및 중간생성물
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
EA201690421A1 (ru) * 2013-08-20 2016-06-30 Инсайт Корпорейшн Положительный эффект в форме увеличения продолжительности жизни у больных с солидными опухолями с повышенными уровнями c-реактивного белка
EP2883959A1 (en) 2013-12-13 2015-06-17 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
CN103897006A (zh) * 2013-12-18 2014-07-02 吉林修正药业新药开发有限公司 一种卡培他滨异构体的制备方法
WO2015191576A1 (en) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
CN104530164A (zh) * 2014-12-31 2015-04-22 辰欣药业股份有限公司 一种卡培他滨的合成工艺
KR20160117060A (ko) 2015-03-31 2016-10-10 이승주 유아용 탁자
CN105646625B (zh) * 2015-12-29 2019-06-11 江苏吴中医药集团有限公司 一种卡培他滨的制备方法
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
TR201702500A2 (tr) * 2017-02-20 2017-07-21 Anadolu Ueniversitesi Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3737376B1 (en) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human diseases
AU2019207626B2 (en) 2018-01-10 2023-10-05 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
WO2019143860A1 (en) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
AR114810A1 (es) 2018-01-30 2020-10-21 Incyte Corp Procesos e intermedios para elaborar un inhibidor de jak
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
AU2020207026A1 (en) 2019-01-11 2021-07-29 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin C and method of manufacture
US12110311B2 (en) 2019-07-17 2024-10-08 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
CN115605492A (zh) 2020-04-21 2023-01-13 配体制药股份有限公司（Us） 核苷酸前药化合物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
EP4382093A1 (en) 2022-12-05 2024-06-12 a Fine House S.A. Oral suspensions comprising capecitabine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1135258A (en) * 1979-06-15 1982-11-09 Richard D'souza Process for the preparation of 5'deoxy-5-fluorouridine
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives

Also Published As

Publication number Publication date
KR100347218B1 (ko) 2003-01-24
CA2103324A1 (en) 1994-06-19
HU211965A9 (en) 1996-01-29
BG98304A (bg) 1994-01-03
AU671491B2 (en) 1996-08-29
NO934671L (no) 1994-06-20
TW372239B (en) 1999-10-21
CZ284788B6 (cs) 1999-03-17
EE03086B1 (et) 1998-04-15
UA39158C2 (uk) 2001-06-15
RU2135511C1 (ru) 1999-08-27
RO112619B1 (ro) 1997-11-28
US5472949A (en) 1995-12-05
FI935616A (fi) 1994-06-19
CN1094056A (zh) 1994-10-26
LT3115B (en) 1994-12-27
EP0602454B1 (en) 1996-04-24
HK1005875A1 (en) 1999-01-29
AU5069093A (en) 1994-06-30
ES2086856T3 (es) 1996-07-01
JPH06211891A (ja) 1994-08-02
FI935616A0 (fi) 1993-12-14
ZA939293B (en) 1994-06-18
HUT65757A (en) 1994-07-28
IL108000A0 (en) 1994-04-12
KR940014428A (ko) 1994-07-18
SK281403B6 (sk) 2001-03-12
SK144493A3 (en) 1994-10-05
PL174100B1 (pl) 1998-06-30
DK0602454T3 (da) 1996-07-29
NZ250414A (en) 1995-12-21
LV10625B (en) 1996-04-20
ATE137244T1 (de) 1996-05-15
RU2493162C1 (ru) 2013-09-20
NO300066B1 (no) 1997-04-01
CZ273193A3 (en) 1994-07-13
GEP20074251B (en) 2007-12-10
HU9303525D0 (en) 1994-04-28
HRP931430B1 (en) 1999-08-31
LTIP1627A (en) 1994-07-15
CN1035617C (zh) 1997-08-13
SI9300648A (en) 1994-09-30
RU2458932C2 (ru) 2012-08-20
YU49411B (sh) 2006-01-16
CA2103324C (en) 1997-12-23
SI9300648B (sl) 2000-06-30
IS4108A (is) 1994-06-19
LV10625A (lv) 1995-04-20
DE69302360D1 (de) 1996-05-30
BG61485B1 (bg) 1997-09-30
DE69302360T2 (de) 1996-10-31
SV1993000080A (es) 1996-01-26
NO934671D0 (no) 1993-12-17
FI112365B (fi) 2003-11-28
EP0602454A1 (en) 1994-06-22
GR3020286T3 (en) 1996-09-30
YU77993A (sh) 1996-10-18
PL301541A1 (en) 1994-06-27
HU218291B (en) 2000-07-28
BR9305089A (pt) 1994-07-05
PH30168A (en) 1997-01-21
SA93140409B1 (ar) 2004-07-24
HRP931430A2 (en) 1998-06-30
MY109282A (en) 1996-12-31
JP2501297B2 (ja) 1996-05-29

Similar Documents

Publication Publication Date Title
UY23697A1 (es) Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo
RU93056196A (ru) N-карбонилзамещенные 5'-дезокси-5-фторцитидина
NZ231983A (en) Substituted 1,3-diazoles and 1,2,4-triazoles; fungicidal compositions, methods for preparation and combating fungal disease
EP0368429A3 (en) Fluor-substituted benzene derivatives
CA2065978A1 (en) Organosilicon compounds containing (meth)acryloxy groups, their preparation and use
FR2702480B1 (fr) Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
HU9202367D0 (en) Preparative for reducing blood pressure
EP0401715A3 (en) Aminoketone compounds

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20131116